Leukemia research · 2010
In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lönnerholm Gudmar, Thörn Ingrid, Sundström Christer, Frost Britt-Marie, Flaegstad Trond, Heyman Mats, Jonsson Olafur Gisli, Harila-Saari Arja, Madsen Hans O, Porwit Anna, Schmiegelow Kjeld, Söderhäll Stefan, Wesenberg Finn, Vettenranta Kim, Larsson Rolf, Forestier Erik
Аннотация
Leukemic cells from 230 children with newly diagnosed B-cell precursor ALL were tested for in vitro drug resistance to a panel of anti-cancer drugs. Minimal residual disease (MRD) was measured by RQ-PCR. During follow-up, 24 relapses occurred in the 159 children with MRD <0.1% day 29. The risk of any relapse was correlated to vincristine and doxorubicin resistance, with a relative risk of 3.7 (95% CI 1.3-10.5; p=0.016) for patients resistant to both drugs. There was a significant correlation also for the subgroup with extra-medullary relapses. Our findings indicate that analysis of drug resistance can add prognostic information to other known risk-factors including MRD.
Предметные рубрики MeSH
AdolescentAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBone Marrow CellsChildChild, PreschoolChromosome AberrationsDoxorubicinDrug Resistance, MultipleDrug Resistance, NeoplasmFemaleFollow-Up StudiesHumansInfantMaleNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaPrednisolonePrognosisRisk FactorsVincristine